Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

March 3, 2016

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
Chronic Heart Failure With Reduced Systolic Function
Interventions
DRUG

Dapagliflozin

DRUG

Dapagliflozin matching placebo

Trial Locations (25)

10016

New York University, New York

11576

St. Francis Hospital, Roslyn

19106

University of Pennsylvania, Philadelphia

20889

Walter Reed National Military Medical Center, Bethesda

21201

University of Maryland, Baltimore

27705

Duke University, Durham

28562

Eastern Nephrology Associates, New Bern

30303

Emory University, Atlanta

32256

First Coast Cardiovascular Institute, Jacksonville

33952

Charlotte Heart Group Research Center, Port Charlotte

36532

Heart Group of the Eastern Shore, Fairhope

37232

Vanderbilt University, Nashville

44195

Cleveland Clinic, Cleveland

48202

Henry Ford Health System, Detroit

55905

Mayo Clinic, Rochester

60181

Advocate Health and Hospitals, Oakbrook Terrace

60201

NorthShore University HealthSystem Research Institute, Evanston

60208

Northwestern University, Evanston

63110

Washington University, St Louis

64108

Truman Medical Center, Kansas City

64111

Saint Luke's Hospital of Kansas City, Kansas City

64804

Freeman Health System, Joplin

75390

University of Texas Southwestern, Dallas

90032

University of Southern Califiornia, Los Angeles

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors
lead

Saint Luke's Health System

OTHER

NCT02653482 - Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure | Biotech Hunter | Biotech Hunter